Nicholas Piramal India Ltd has initiated two basic
research programmes to screen patient samples in the diabetes
and cancer segments in order to develop biomarkers that
could eventually lead to a targeted new drug development.
company has recently forged a cancer-related alliance
with Chennai''s Apollo Hospitals Group for the molecular
profiling of tumors.
will do a "blind" study of the tumour samples
provided by the hospital and compare the data with the
hospital''s patient response to conventional therapy.
could be an external substance or a feature in the human
body that helps indicate a pattern in the patient''s response
tool used for target identification, the biomarker technology
is getting more refined over the years and it improves
the chance of discovering a drug, observes a senior researcher
with a clinical research organisation.
company is finalisng a similar study with the diabetology
group of Chennai''s
Sri Ramachandra Medical College and Research Institute
that would help evaluate specific markers for diabetes.